Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Chemaly, Roy F  [Clear All Filters]
2024
Avadhanula V, Agustinho DPaiva, Menon VKumar, Chemaly RF, Shah DP, Qin X, Surathu A, Doddapaneni H, Muzny DM, Metcalf GA, et al. Inter and intra-host diversity of RSV in hematopoietic stem cell transplant adults with normal and delayed viral clearance. Virus Evol. 2024;10(1):vead086.
Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TLynn, Rondon G, Sassine J, Spallone A, Srinivasan K, Ramdial J, Alousi A, et al. Mortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience. Clin Microbiol Infect. 2024.
2022
Hayase E, Hayase T, Jamal MA, Miyama T, Chang C-C, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, et al. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022;185(20):3705-3719.e14.
Khawaja F, Srinivasan K, Spallone A, Feldman A, Cantu S, Ariza-Heredia E, Dvordak T, Alousi A, Ahmed S, George M, et al. Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: lessons learned. Am J Infect Control. 2022.
2021
Yong MK, Shigle TLynn, Kim Y-J, Carpenter PA, Chemaly RF, Papanicolaou GA. American Society of Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther. 2021.
Sharma A, Bhatt NS, St Martin A, Abid MBilal, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales M-A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.
2020
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
2018
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, et al. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2018.
Foolad F, Aitken SL, Chemaly RF. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Rev Clin Pharmacol. 2018.
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, et al. Pulmonary impairment following respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2018.
2016
Langman LJ, Nesher L, Shah DP, Azzi JM, Shpall EJ, Rezvani K, Black JL, Chemaly RF. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn. 2016.
Shah DP, Shah PK, Azzi JM, Chaer FEl, Chemaly RF. Human Metapneumovirus Infections in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients: A Systematic Review. Cancer Lett. 2016.
2015
Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2015.